We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / PRODUCT PORTFOLIO
OTHER THERAPEUTIC AREAS

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.
Product Indication Dosage form Strength
Amitriptyline Major depressive disorders and anxiety Tablets 10, 25, 50, 75 and 100 mg
Amitriptyline Major depressive disorders and anxiety XR tablets 75 mg
Baclofen Spasticity Injection 10 mg/5 ml and 10 mg/20 ml
Clonazepam Epilepsy Tablets 0.5 mg and 2 mg
Duloxetine * Major depressive disorders, neuropathic pain, anxiety Gastro resistant hard capsules 90 and 120 mg
Fampridine Multiple sclerosis XR tablets 10 mg
Fingolimod Multiple sclerosis Capsules 0.5 mg
Lacosamide Epilepsy Oral solution 10 mg/ml
Methocarbamol Muscle spasms, pain Film-coated tablets 1.5 mg
Nabilone * Antiemetic Film-coated tablets 1 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Orodispersable tablets 25 and 50 mg
Rotigotine Parkinson's Patches 1, 2, 3, 4, 6 and 8 mg/24h
Sodium Oxybate Narcolepsy Oral solution 500 mg/ml
Tranylcypromine Depression Film-coated tablets 10, 20 and 40 mg
FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.